Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Hebrew Validation
New Gold Standard for Olfactory Assessment: Validating the Hebrew ‘Sniffin’ Sticks’ Test
Posted innews Otorhinolaryngology

New Gold Standard for Olfactory Assessment: Validating the Hebrew ‘Sniffin’ Sticks’ Test

Posted by MedXY By MedXY 01/18/2026
Researchers have validated a Hebrew version of the 'Sniffin' Sticks' identification test, providing a highly reliable and culturally adapted tool for diagnosing olfactory dysfunction in Israel with a sensitivity of 93.3%.
Read More
  • Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
  • Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
  • Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis
  • Targeting CXCR1/2 Ligands: Eltrekibart Demonstrates Clinical Potential in Phase 2 Hidradenitis Suppurativa Trial
  • Saturated Saline Immersion: A Novel and Noninvasive Approach for Refractory Plantar Warts
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in